Category - Developments

DarioHealth (NASDAQ:DRIO) has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of the art...

DarioHealth (NASDAQ:DRIO) has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes that will use DarioHealth to run and track blood glucose...

Lipocine (NASDAQ:LPCN) announced receipt of $10-million in January by means of a loan and security agreement with Silicon Valley Bank. “This debt facility strengthens our balance sheet and provides increased...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients...

Ortho Regenerative Technologies (CSE:ORTH) announced that a peer-reviewed article detailing the tissue regeneration properties of its implants was published in the current issue of Journal of Tissue Engineering and...

Pixium Vision (FR0011950641-PIX) announced the first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss...

IntelGenx (OTCQX:IGXT; TSXV:IGX) has initiated the Phase 2a proof-of- concept clinical trial with its Montelukast VersaFilm in Alzheimer’s disease patients, following clearance by Health Canada. The Phase 2a trial is a...

Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid...

NeutriSci International (OTCQB:NRXCF; TSX-V:NU; FRANKFURT:1N9) and Scientus Pharma have entered into a major R&D memorandum of understanding to share their technologies to develop, test, produce, and distribute a...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) expects revenue of about  $1.9-million for the fourth quarter of 2017, compared to nil in the year earlier quarter, and up about 30% sequentially from the third quarter of 2017...